Cited 0 times in 
Cited 0 times in 
The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks
https://orcid.org/0000-0001-5525-6861Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.